Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

UNC Libraries(2020)10.17615/gmbp-hs07Source: DataRank Database

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors is a research paper published in UNC Libraries (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: bronzeTopics (23)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Celeste Lindley,Frances A. Collichio ORCID,Lisa A. Carey ORCID,Bert H. O’Neil ORCID,E. Claire Dees

Live enrichment

PubMed:18327587

National Institutes of Health

Grant: 1K23RR016536-01

P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLY

National Institutes of Health

Grant: 5R01CA102278-03

Dual Proteasome and MAPK Inhibition in Cancer Therapy

National Institutes of Health

Grant: 3M01RR000046-39S2

STUDY OF CONTROLLED RELEASE DARIFENACINE IN TREATMENT OF IBS

National Institutes of Health

Grant: 5P50CA058223-12

SPORE in Breast Cancer

bronzeLicense: Springer TDM

https://doi.org/10.1007/s00280-008-0716-8

https://europepmc.org/articles/pmc4312589?pdf=render

https://dx.doi.org/10.17615/gmbp-hs07

https://pubmed.ncbi.nlm.nih.gov/18327587

https://dx.doi.org/10.1007/s00280-008-0716-8

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

Keywords

AdultMaleDose-Response Relationship, DrugMaximum Tolerated DoseGastrointestinal DiseasesMiddle AgedBoronic AcidsCombined Modality TherapyHematologic DiseasesNeoplasm ProteinsPolyethylene GlycolsBortezomibDoxorubicinNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsLiposomesHumansFemaleFatigueAged

Sustainable Development Goals

SDG 3: 3. Good health